{"id":148,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2007-05-31","marketCap":3118.13,"name":"Amicus Therapeutics Inc","phone":"12159217600.0","outstanding":287.12,"symbol":"FOLD","website":"https://www.amicusrx.com/","industry":"Biotechnology"},"price":10.875,"year":2023,"month":10,"day":11,"weekday":"Wednesday","title":"How Changes in Consumer Behavior and Preferences are Influencing the Performance of Amicus Therapeutics Inc's Stock","date":"2023-10-11","url":"/posts/2023/10/11/FOLD","content":[{"section":"Introduction","text":"Amicus Therapeutics Inc. is a biotechnology company specializing in the development of therapies for rare and orphan diseases. As with any stock, the performance of Amicus Therapeutics Inc. is influenced by various factors, including changes in consumer behavior and preferences. In this article, we will explore how shifts in technology, demographics, and consumption patterns have the potential to impact the company's stock performance."},{"section":"Shifts in Technology","text":"Technology plays a significant role in shaping consumer behavior and preferences. Advances in technology have made it easier for consumers to access information about pharmaceutical companies and their products. This has led to increased scrutiny and demands for transparency from consumers. Additionally, developments in telehealth and digital health solutions have impacted the way patients interact with healthcare providers. These technological advancements can influence the adoption and success of Amicus Therapeutics Inc.'s therapies, thereby impacting the company's stock performance."},{"section":"Changing Demographics","text":"Demographic shifts can also have a profound impact on consumer behavior and preferences. Changing demographics, such as an aging population, can lead to increased demand for treatments and therapies targeting age-related diseases. Amicus Therapeutics Inc. focuses on rare and orphan diseases, many of which disproportionately affect specific demographic groups. As the demographics of the population change, it can have implications for the demand and market potential for the company's therapies, ultimately influencing its stock performance."},{"section":"Consumption Patterns","text":"Consumer consumption patterns are constantly evolving, driven by various factors such as changing lifestyles, social trends, and environmental consciousness. In the healthcare industry, there is a growing preference for personalized medicine and targeted therapies. Amicus Therapeutics Inc. is at the forefront of developing precision medicine for rare genetic diseases. The evolving preference for personalized treatments aligns well with the company's focus, potentially driving increased demand for its therapies. This shift in consumption patterns can positively impact the company's stock performance."},{"section":"Conclusion","text":"Changes in consumer behavior and preferences have a significant influence on the stock performance of companies like Amicus Therapeutics Inc. Technological advancements, changing demographics, and shifting consumption patterns all play a role in shaping the demand for the company's therapies. By staying attuned to these changes and adapting their strategies accordingly, Amicus Therapeutics Inc. can position itself for success in the evolving healthcare landscape."}],"tags":["stock","Short","Biotechnology"],"news":[{"category":"company","date":1696845840,"headline":"Biotech Alert: Searches spiking for these stocks today","id":123041802,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3152226251"},{"category":"company","date":1696762800,"headline":"This Rare Disease Pharma Is a Hidden Gem","id":123030688,"image":"","symbol":"FOLD","publisher":"Yahoo","summary":"Amicus Therapeutics, Inc.  is commercial-stage biopharmaceutical company developing therapies for rare diseases.  With two approved products already, this Philadelphia-based biotech is a prime choice for an options play.  Amicus recently won approval for combination therapy for Pompe disease, a rare genetic disorder that leads to weakness in the heart and other muscles because of a lack of a special enzyme that breaks down a type of sugar for use as energy.","url":"https://finance.yahoo.com/m/b8e6665a-6585-3c23-8657-68e4bf22be22/this-rare-disease-pharma-is-a.html"},{"category":"company","date":1696549552,"headline":"‘Stay Invested Through the Uncertainty’: J.P. Morgan Says Stocks Could Reach New Highs Next Year — Here Are 2 Names to Pounce on Now","id":122994276,"image":"https://media.zenfs.com/en/tipranks_452/33c61bbdd600ea3aef56604ae4334f45","symbol":"FOLD","publisher":"Yahoo","summary":"What should we make of today’s market conditions? Investors are digesting how the Federal Reserve’s ‘higher for longer’ interest rate policy will impact the economy, and they’re not pleased with the prospect. Other challenges on the horizon include the ongoing Congressional budget battles, lingering inflation, the evaporation of consumer savings and purchasing power, and concerns over China’s incendiary combination of slowing growth, geopolitical ambition, and approaching demographic collapse. T","url":"https://finance.yahoo.com/news/stay-invested-uncertainty-j-p-234552251.html"},{"category":"company","date":1696489267,"headline":"Insider Sell: Amicus Therapeutics Inc President \u0026 CEO Bradley Campbell Sells 11,700 Shares","id":122975501,"image":"https://media.zenfs.com/en/us.finance.gurufocus/4b4e1d7a1739789353c10cbb1ad78af3","symbol":"FOLD","publisher":"Yahoo","summary":"On October 2, 2023, Bradley Campbell, President \u0026 CEO of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 11,700 shares of the company.","url":"https://finance.yahoo.com/news/insider-sell-amicus-therapeutics-inc-070107873.html"},{"category":"company","date":1696330800,"headline":"Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023","id":122926153,"image":"https://s.yimg.com/ny/api/res/1.2/F_nQquQSKrOL5EGt83b_tA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDM-/https://media.zenfs.com/en/globenewswire.com/6723cd6774a73c25fd14e691c5eb8722","symbol":"FOLD","publisher":"Yahoo","summary":"PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023 in Charleston, SC. Oral Presentation: Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with algl","url":"https://finance.yahoo.com/news/amicus-therapeutics-announces-presentation-posters-110000451.html"},{"category":"company","date":1696249200,"headline":"Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration","id":122900874,"image":"https://s.yimg.com/ny/api/res/1.2/F_nQquQSKrOL5EGt83b_tA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDM-/https://media.zenfs.com/en/globenewswire.com/6723cd6774a73c25fd14e691c5eb8722","symbol":"FOLD","publisher":"Yahoo","summary":"Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackston","url":"https://finance.yahoo.com/news/amicus-therapeutics-blackstone-enter-430-122000099.html"},{"category":"company","date":1696244100,"headline":"Amicus, Blackstone enter $430M strategic financing partnership","id":122906544,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3141973822"},{"category":"company","date":1696235940,"headline":"Amicus in pact with Blackstone for $430M financing","id":122906545,"image":"","symbol":"FOLD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3141878427"},{"category":"company","date":1696192200,"headline":"WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease","id":122906547,"image":"","symbol":"FOLD","publisher":"PR Newswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=fsgy5g24y8"},{"category":"company","date":1696073141,"headline":"JP Morgan Maintains Amicus Therapeutics (FOLD) Overweight Recommendation","id":122881857,"image":"","symbol":"FOLD","publisher":"Fintel","summary":"","url":"https://fintel.io/news/jp-morgan-maintains-amicus-therapeutics-fold-overweight-recommendation-940"},{"category":"company","date":1695992940,"headline":"Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug","id":122864784,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"FOLD","publisher":"Yahoo","summary":"Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.","url":"https://finance.yahoo.com/news/amicus-fold-gets-fda-approval-130900423.html"},{"category":"company","date":1695990120,"headline":"Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023","id":122869697,"image":"","symbol":"FOLD","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=hwlqu9zkkh"},{"category":"company","date":1695985214,"headline":"Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter","id":122860154,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/931409422/image_931409422.jpg?io=getty-c-w1536","symbol":"FOLD","publisher":"SeekingAlpha","summary":"Shares of Amicus Therapeutics decline after FDA approval of Pombiliti and Opfolda for late-onset Pompe disease. Read more about FOLD stock here.","url":"https://seekingalpha.com/article/4638122-amicus-therapeutics-limited-label-for-pombiliti-and-opfolda-and-why-may-not-matter"},{"category":"company","date":1695967800,"headline":"JPMorgan ups Amicus target to $19, adds to Analyst Focus List","id":122865373,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3138444740"},{"category":"company","date":1695967440,"headline":"Amicus added to Analyst Focus List at JPMorgan","id":122865374,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3138439942"},{"category":"company","date":1695965460,"headline":"Amicus price target raised to $19 from $16 at BofA","id":122865375,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3138411805"},{"category":"company","date":1695963780,"headline":"Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session","id":122862387,"image":"","symbol":"FOLD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3138388152"},{"category":"company","date":1695963720,"headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Johnson \u0026 Johnson (JNJ) and Amicus (FOLD)","id":122862626,"image":"","symbol":"FOLD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3138387289"},{"category":"company","date":1695913702,"headline":"UPDATE 1-US FDA approves Amicus Therapeutics' muscle disorder treatment","id":122835303,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"FOLD","publisher":"Yahoo","summary":"Amicus Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a muscle disorder called Pompe disease.  The health regulator last October extended its review for a second time following delays in inspections caused by pandemic-related travel restrictions.  The therapy is indicated for use in adults living with late-onset Pompe disease and those without an improvement on their current enzyme replacement therapy, the company said.","url":"https://finance.yahoo.com/news/1-us-fda-approves-amicus-150822325.html"},{"category":"company","date":1695912060,"headline":"Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease","id":122835304,"image":"https://s.yimg.com/ny/api/res/1.2/YNlT0_oJd22mX8jvKRQYQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNzg-/https://media.zenfs.com/en/globenewswire.com/5062b4778667a5a1a61ba0d2fee06f03","symbol":"FOLD","publisher":"Yahoo","summary":"Pombiliti + Opfolda Logo Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (migl","url":"https://finance.yahoo.com/news/amicus-therapeutics-announces-fda-approval-144100339.html"},{"category":"company","date":1695911520,"headline":"Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark","id":122835305,"image":"https://media.zenfs.com/en/ibd.com/62147566276b3a75eab1ea938001a116","symbol":"FOLD","publisher":"Yahoo","summary":"Amicus Therapeutics just cleared that benchmark with an upgrade from 77 to 82.  Amicus Therapeutics is trying to complete a consolidation with a 14.10 buy point.  Amicus Therapeutics earns the No. 39 rank among its peers in the Medical-Biomed/Biotech industry group.","url":"https://finance.yahoo.com/m/4a15dd77-693e-390c-a16d-a10c83a87276/amicus-therapeutics-stock.html"},{"category":"company","date":1695898800,"headline":"Scan of Amicus label 'doesn't raise any major questions,' says Stifel","id":122838998,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3137076481"},{"category":"company","date":1695897000,"headline":"Amicus wins FDA approval of Pompe disease treatment","id":122839000,"image":"","symbol":"FOLD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3137036165"},{"category":"company","date":1695895800,"headline":"Amicus trading resumes","id":122839001,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3137010845"},{"category":"company","date":1695894720,"headline":"Amicus trading to resume at 11:10 am ET","id":122839002,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3136988406"},{"category":"company","date":1695894240,"headline":"Amicus announces FDA approval of Pombiliti plus Opfolda","id":122839003,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3136977277"},{"category":"company","date":1695886140,"headline":"Amicus trading halted, news pending","id":122839004,"image":"","symbol":"FOLD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3136817538"},{"category":"company","date":1695786000,"headline":"Amicus closes up 5% as it expects approval of Pompe disease therapy","id":122839005,"image":"","symbol":"FOLD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135714718"}]}